Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000275

Drug Information
SynonymsD00094; Ro 1-5488; LGD-1057; Atralin; IDI1_033970; CHEBI:50648; LG-100057; Retisol-A; UPCMLD-DP097; BML2-E05; Alitretinoin; Retinova; Effederm; Spectrum5_001746; NSC122758; STOCK1N-38565; Tretinoina; DB00755; Nexret; 9C-RA; HMS1361K22; 56573-65-0; Tretinoin Zinc Salt; Tretinoine; Tretinoino; R 2625; 9-cis-RA; Avitoin; 187175-63-9; NCGC00161590-06; HMS1361K17; Renova (TN); Atra-IV; Lopac0_001061; AC1L9GWO; IDI1_033965; NCGC00021808-07; NCGC00021808-04; LMPR01090022; Acid, trans-Retinoic; (9cis)-retinoic acid; D02815; b-Retinoic acid; STK801887; AGN-192013; NSC 122758; 9-CIS-RETINOIC ACID; Acid, Vitamin A; MLS002222211; BIDD:PXR0081; CCRIS 7098; DB00982; NCGC00021808-14; A-Acido (Argentina); LGD 1057; BAL-4079; NSC-659772; Spectrum5_001933; AGN 100335; HMS1989K22; LMPR01090019; Tretin M; Solage; I14-2351; Panretin; trans Retinoic Acid; Stieva-A; Retinoic acid; Retacnyl; Aknoten; Alitretinoin [USAN]; HMS2089D20; Acnavit [Denmark]; Panrexin; HMS502N05; Aberela [Norway]; [3H]Retinoic acid; Airol; HSDB 7186; Tri-Luma; Aknefug; BPBio1_000082; CCRIS 3294; Retionic acid; Salt, Tretinoin Zinc; DB00523; LS-1154; .beta.-Retinoic acid; CID449171; Avitoin [Norway]; LGD 100057; NCGC00021808-05; L000833; NCGC00161590-05; MLS000028588; Prestwick_424; NCGC00017280-06; Epi-aberel; SR-01000000239-14; Effederm [France]; alitretinoina; HMS1791K17; Vitinoin; CPD000058245; 9(Z)-Retinoic acid; HMS1791K22; AC1L9MT9; UNII-1UA8E65KDZ; NCGC00017280-17; Aberel; CHEMBL705; Vesanoid (TN); Accutane Roche; EU-0101061; 9-cis Retinoic Acid; HMS1568D16; AC-6824; SAM002264647; Vesnaroid; NCGC00161590-01; 7005-78-9; MolPort-002-507-281; Zinc Salt, Tretinoin; HMS1921D14; A-Vitaminsyre; AC1Q1J2J; UPCMLD-DP097:002; TRETINON; beta-Ra; AKOS000280845; ST057075; R2625_SIGMA; nchembio861-comp8; Acid, Retinoic; C00777; Panretin Gel; ALRT-1057; Tretinoinum; Cordes vas; beta-Retinoic acid; tretinoin liposome; SPECTRUM1502016; 5300-03-8; BAL4079; S1653_Selleck; D014212; nchembio.106-comp3; Retinoate; SR-01000000239; SR-05000013784; ATRA; Dermairol; NCGC00021808-06; alitretinoine; trans-Retinoic acid; NSC 659772; AT-RA; tretinoin; EINECS 206-129-0; Toctino; Retin-A Micro; BSPBio_001495; REA; 1n4h; Spectrum5_001935; 9-cis RA; Stieva-a Forte; 9-CRA; SR-05000013784-1; Prestwick3_000257; Tretinoin (TN); BIDD:GT0483; Panretin (TN); Lsotretinoin; 302-79-4; UNII-5688UTC01R; Retin A (TN); NCGC00161590-04; Avita (TN); Vesanoid; 9 Cis Retinoic Acid; NCGC00161590-03; Atragen; PDT-002-002; I04-0008; MolPort-000-883-857; Acnavit; R0064; Cordes VAS [Germany]; Avita Gel; NCGC00021808-15; BB_NC-1005; BML2-E06; NSC659772; CHEBI:15367; Betarretin; NCGC00161590-07; bmse000562; IDI1_000903; BSPBio_000074; BRN 2057223; AGN 192013; Aberela; 9CRA; 9-cis-Tretinoin; nchembio.154-comp2; all-trans-Tretinoin; BSPBio_001500; LS-1328; Eudyna; HSDB 2169; Prestwick2_000257; Retin-A; Alitretinoin (USAN); CID444795; Vitamin A acid; NCGC00021808-09; CHEMBL38; Ro-04-4079; C15493; NCGC00161590-02; NSC-122758; Panretyn; Renova; HMS1989K17; HMS2092N11; R4643_SIGMA; alitretinoinum; SMR000058245; Retin A; ALRT 1057; MLS001076515; UPCMLD-DP097:001; MLS002207234    
Trade NamePanretin    
CompanyLigand Pharmaceuticals    
IndicationKaposi's sarcomaApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAntineoplastic Agents    
CAS NumberCAS 5300-03-8
PubChem Compound IDCID 449171.    
PubChem Substance IDSID 509159.    
SuperDrug ATC IDL01XX22;    
SuperDrug CAS ID005300038;    
TargetRetinoic acid receptor alphaAgonist[2][3][4]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2Alitretinoin: a new treatment option for chronic refractory hand eczema. Hautarzt. 2008 Sep;59(9):703-4, 706-9. To Reference
Ref 3Alitretinoin: a comprehensive review. Expert Opin Investig Drugs. 2008 Mar;17(3):437-43. To Reference
Ref 4Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol. 2004 Dec;140(12):1453-9. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543